Japan Oral Anti-Diabetic Drug Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| Market Size (2024) | USD 2.42 Billion |
| Market Size (2029) | USD 3.02 Billion |
| CAGR (2024 - 2029) | 4.60 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Japan Oral Anti-Diabetic Drug Market Analysis
The Japan Oral Anti-Diabetic Drug Market size is estimated at USD 2.42 billion in 2024, and is expected to reach USD 3.02 billion by 2029, growing at a CAGR of 4.60% during the forecast period (2024-2029).
Japan's oral anti-diabetic drug market is on a growth trajectory, bolstered by a surge in diabetes cases and proactive industry measures, such as enhanced product offerings and expanded production capacities.
Given the escalating diabetic population in Japan, the demand for diabetes drugs and devices, pivotal for blood glucose management, is expected to increase. Data from the IDF Diabetes Atlas reveals a widespread distribution of diabetes across age groups, with a notable concentration among the working-age demographic. In 2022, Japan had 5.5 thousand diabetic people under 20, 43.3 thousand aged 20-59, and 30.5 thousand above 60. Such a high concentration of diabetic people in the working-age bracket significantly impacts the country's economic healthcare burden. The IDF Diabetes Atlas projects Japan's total diabetes-related health expenditure to reach USD 32.8 million by 2030.
Japan's aging demographic, which is vulnerable to diseases, coupled with a rise in obesity due to sedentary lifestyles and irregular eating habits, are key drivers behind the nation's escalating diabetes rates. As of December 2023, approximately 30% of Japan's population was aged 65 or older, as highlighted by the Ministry of Internal Affairs and Communications in May 2024. With this aging trend, Japan is bracing for a further uptick in diabetes cases, which would lead to increased demand for oral anti-diabetic drugs.
The increasing prevalence of diabetes, driven by an aging population and lifestyle factors, is expected to significantly boost the market for oral anti-diabetic drugs in Japan.
Japan Oral Anti-Diabetic Drug Market Trends
The GLP-1 Receptor Agonists Segment is Expected to Hold a Significant Market Share
In Japan's pharmaceutical landscape, GLP-1 receptor agonists (GLP-1 RAs) are carving out a crucial niche, especially for managing Type 2 diabetes and obesity. These medications help regulate blood glucose levels and are increasingly recognized for addressing obesity. They are administered primarily through injectables.
In Japan, adult patients grappling with hypertension, hyperlipidemia, or Type 2 diabetes mellitus turn to GLP-1 RAs when dietary changes and exercise fall short. This wide-ranging application highlights the significance of GLP-1 RAs in tackling prevalent health challenges in Japan.
Insights from a study released in September 2023 by Elsevier BV showed the real-world effectiveness of GLP-1 RAs in Japan. The research monitored patients over time, noting positive shifts in key clinical metrics like HbA1c (glycated hemoglobin), body weight (BW), and body mass index (BMI) in GLP-1 RA-naive Type 2 diabetes patients. Impressively, these enhancements were evident even in the elderly, underscoring the medication's broad efficacy.
Such findings help boost the clinical credibility of GLP-1 RAs and foster greater acceptance among both healthcare professionals and patients. Given Japan's emphasis on effective long-term solutions for chronic ailments, the pronounced benefits of GLP-1 RAs in managing diabetes and obesity resonate strongly.
In April 2023, the GLP-1 RA segment debuted Mounjaro, a collaboration between Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation (MTPC). Mounjaro is the inaugural sustained-release formulation globally, merging glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. By stimulating both GIP and GLP-1 receptors, this innovative medication heralded a transformative leap in diabetes management.
Mounjaro's entry is poised to amplify the GLP-1 RA segment’s footprint in Japan. Engaging multiple pathways for glucose regulation emerges as a promising therapeutic alternative, potentially outshining current treatments and enhancing patient outcomes.
With Japan's unwavering commitment to pioneering treatments for chronic ailments, GLP-1 RAs are set to be pivotal in the nation's healthcare narrative. The continuous influx of novel medications, coupled with persistent research endeavors, underscores the growing prominence of GLP-1 RAs in bolstering patient health and propelling market expansion.
The Increasing Diabetes Population in Japan is Driving the Market
Diabetes is a global health concern. Japan’s escalating diabetes rates are raising alarms, urging swift action from healthcare authorities and stakeholders.
The Ministry of Health, Labor, and Welfare in Japan has identified diabetes as a critical health priority. Notably, type 2 diabetes is proving to be a significant economic burden, especially for patients with comorbid conditions such as hypertension and hyperlipidemia or those facing complications.
Diabetes is increasing across all age groups in Japan, a trend attributed to a growing obese population, unhealthy dietary choices, and sedentary lifestyles. Projections from the International Diabetes Federation (IDF) indicate that Japan's diabetic population will reach 10,542.7 thousand by 2030 and 10,117.9 thousand by 2045.
As the diabetic population rises, Japan is witnessing a surge in new product launches and guideline revisions. In May 2024, the Japan Diabetes Society issued updated guidelines emphasizing the safe usage of diabetes medications, particularly incretin-related drugs. This initiative was prompted by the increased adoption of GLP-1 receptor agonists, recognized for their efficacy in handling blood sugar and aiding weight loss. These drugs also show promise in addressing diabetes-related kidney and cardiovascular issues, especially with the introduction of oral formulations.
Japan's battle with diabetes presents both challenges and opportunities. The nation's commitment to addressing this health crisis through innovative solutions and updated protocols will be crucial in mitigating the future health and economic impacts of diabetes.
Japan Oral Anti-Diabetic Drug Industry Overview
The Japanese oral anti-diabetes drug market is semi-consolidated, with a few major manufacturers, such as Eli Lilly and Company, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, having a global market presence.
Japan Oral Anti-Diabetic Drug Market Leaders
-
Sanofi
-
Eli Lilly and Company
-
Pfizer Inc.
-
AstraZeneca
-
Johnson And Johnson
*Disclaimer: Major Players sorted in no particular order
Japan Oral Anti-Diabetic Drug Market News
- June 2024: Eli Lilly and Company made significant investments in boosting its production capacity for drugs targeting obesity and diabetes. This move came as the company lifted restrictions on shipping its flagship diabetes drug, Manjaro, in Japan.
- April 2023: Eli Lilly Japan and Mitsubishi Tanabe Pharma commenced the sale of tirzepatide (trade name: Manjaro Subcutaneous Injection), a receptor agonist for GIP)/glucagon-like peptide (GLP)-1 receptors. This medication, which stimulates glucose-dependent insulin secretion, was granted approval in September 2022 for treating type 2 diabetes and was subsequently approved for NHI in March 2023.
Japan Oral Anti-Diabetic Drug Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions And Market Definition
1.2 Scope Of The Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence Of Diabetes
4.2.2 Reimbursement Policies For Diabetes Oral Medications
4.3 Market Restraints
4.3.1 Stringent Regulatory Requirements For Product Approval
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Drug Type
5.1.1 Biguanides
5.1.2 Alpha-Glucosidase Inhibitors
5.1.3 GLP-1 Receptor Agonists
5.1.4 SGLT-2 Inhibitors
5.1.5 DPP-4 Inhibitors
5.1.6 Others
5.2 By End Users
5.2.1 Hospitals/Clinics
5.2.2 Personal/Home Care Settings
5.2.3 Others
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population (2021 - 2029)
6.2 Type-2 Diabetic Population (2021 - 2029)
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda Pharmaceutical Company Limited
7.1.2 Novo Nordisk A/S
7.1.3 Pfizer Inc.
7.1.4 Eli Lilly and Company
7.1.5 Johnson And Johnson
7.1.6 Astellas Pharma Inc.
7.1.7 Boehringer Ingelheim International GmbH
7.1.8 Merck And Co., Inc.,
7.1.9 AstraZeneca
7.1.10 Bristol-Myers Squibb Company
7.1.11 Novartis AG
7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Japan Oral Anti-Diabetic Drug Industry Segmentation
Oral anti-diabetes drugs help manage blood glucose levels in patients whose bodies still produce some insulin, such as those with type 2 diabetes.
The Japanese oral anti-diabetic drug market is segmented by drugs and end users. By drug, the market is segmented into biguanides, alpha-glucosidase inhibitors, glucagon-like peptide-1(GLP-1) receptor agonists, sodium-glucose cotransport-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and others. By end user, the market is segmented into hospitals/clinics, personal/home care settings, and others. The report offers the value (USD) for all the above segments.
| By Drug Type | |
| Biguanides | |
| Alpha-Glucosidase Inhibitors | |
| GLP-1 Receptor Agonists | |
| SGLT-2 Inhibitors | |
| DPP-4 Inhibitors | |
| Others |
| By End Users | |
| Hospitals/Clinics | |
| Personal/Home Care Settings | |
| Others |
Japan Oral Anti-Diabetic Drug Market Research FAQs
How big is the Japan Oral Anti-Diabetic Drug Market?
The Japan Oral Anti-Diabetic Drug Market size is expected to reach USD 2.42 billion in 2024 and grow at a CAGR of 4.60% to reach USD 3.02 billion by 2029.
What is the current Japan Oral Anti-Diabetic Drug Market size?
In 2024, the Japan Oral Anti-Diabetic Drug Market size is expected to reach USD 2.42 billion.
Who are the key players in Japan Oral Anti-Diabetic Drug Market?
Sanofi, Eli Lilly and Company, Pfizer Inc., AstraZeneca and Johnson And Johnson are the major companies operating in the Japan Oral Anti-Diabetic Drug Market.
What years does this Japan Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?
In 2023, the Japan Oral Anti-Diabetic Drug Market size was estimated at USD 2.31 billion. The report covers the Japan Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Japan Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Japan Oral Anti-Diabetic Drug Industry Report
Statistics for the 2024 Japan Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Japan Oral Anti-Diabetic Drug analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Japan Oral Anti-Diabetic Drug Market Report Snapshots
